Clinical Scorecard: Interactions of Elements Influencing Chemoprotection in the Bone Marrow Niche of Acute Myeloid Leukemia
At a Glance
Category
Detail
Condition
Acute Myeloid Leukemia (AML)
Key Mechanisms
Bone marrow microenvironment interactions, including stromal, vascular, immune, and metabolic components that promote leukemia progression and chemoresistance.
Target Population
Patients with Acute Myeloid Leukemia (AML)
Care Setting
Oncology and hematology clinics
Key Highlights
AML is characterized by the accumulation of immature myeloid cells in the bone marrow.
The bone marrow niche plays a critical role in regulating leukemia progression and treatment response.
Key signaling pathways involved include the CXCL12–CXCR4 axis and JAK/STAT.
Leukemic cells remodel the bone marrow niche to evade chemotherapy.
Emerging therapies target the AML niche to improve treatment outcomes.
Guideline-Based Recommendations
Diagnosis
Utilize genomic profiling for AML diagnosis.
Management
Consider therapies targeting the AML niche, including CXCR4 inhibitors and immune-based treatments.
Monitoring & Follow-up
Monitor for minimal residual disease and relapse.
Risks
High relapse rates and persistence of therapy-resistant leukemic stem cells.
Patient & Prescribing Data
Patients diagnosed with Acute Myeloid Leukemia (AML).
Addressing both leukemic cells and their supportive microenvironment may enhance treatment efficacy.
Clinical Best Practices
Incorporate strategies that disrupt stromal and vascular signaling in treatment plans.
Evaluate the role of extracellular vesicles and metabolic changes in AML management.
